

SECTOR UPDATE

Gaming – Malaysia

Remains A Good Shelter, Value Deliverer

The gaming sector remains both a good shelter amid the current bearish sentiment, and a deliverer of capital gains as earnings recover strongly through 2023. We favour the casino subsector for its sharp earnings recovery, capacity restoration and external opportunities (eg GENM's bid for a downstate New York concession). Nevertheless, the NFO subsector's sharp pullback provides an excellent entry point for yield-hungry investors. Maintain OVERWEIGHT.

WHAT'S NEW

- **Proven defensiveness, while expected to deliver good gains.** We continue to expect the gaming sector's defensive fundamentals to be largely shielded from ongoing market volatilities amid the tightening global monetary policies. To note, the gaming sector mostly outperformed the FBMKLCI index during market sell-downs (refer to RHS chart) over the past three decades. Furthermore, both the casino and NFOs subsectors are poised to chart meaningful earnings recovery from 2020-21's low base which were disrupted by the COVID-19 pandemic-induced restrictions.
- **Casino subsector: Earnings recovery to maintain steady upward slope.** With the post-pandemic-peak's progressive hotel and gaming capacity restoration, the Genting Group's earnings will rebound sharply in 2H22 through to 2023. To note, Malaysian authorities have abolished most of the COVID-19 curbs since 2Q22 and recently removed the indoor mask mandate, allowing Genting Malaysia's (GENM) Resorts World Genting (RWG) to operate at full capacity. Meanwhile, RWG also further ramped up its hotel capacity to >7,600 rooms (2Q22: 6,000 rooms) to cater to the strong demand.
- **Genting Group could benefit from many potential event catalysts,** most prominently GENM's bid for a downstate New York gaming concession (RFP submission expected to be in Oct 22). Other events worth monitoring include GENT's investee TauRx Pharmaceutical's clinical trial progress update and GENM's surprise bid for Macau gaming concession.
- **NFO subsector:** Earnings recovery lagging market expectations. Disappointingly, both Magnum and Sports Toto (SPTOTO) are having difficulties restoring their pre-pandemic earnings dynamic. Ticket sales have been stuck at about 80-85% of pre-pandemic levels in the past few quarters despite the governments' gradual easing of various pandemic-related social distancing constraints, which we attribute to the NFOs' progressive market share losses to illegal operators amid a shift in punters' habits towards executing bets through these illegal bookies.

ACTION

- **Maintain OVERWEIGHT with a preference for the casino subsector.** We continue to bet on sharp earnings recoveries for the Genting Group, and do not foresee any duty hikes for sin stocks in the upcoming Budget 2023. Our top picks are GENM and GENT, with target prices of RM4.00 and RM6.92. For the NFO subsector, maintain BUY on Magnum and SPTOTO with lowered target prices of RM2.00 and RM2.19 respectively as we reduced our 2023 earnings assumptions to factor in the slower-than-expected recovery.

PEER COMPARISON

Segment/Company	Ticker	Rec	Price @ 3 Oct 22 (RM)	Target Price (RM)	Market Cap (US\$m)	EV/EBITDA 2022F (x)	Yield 2022F (%)	PE 2022F (x)
Gaming – Casino								
Genting Malaysia	GENM MK	BUY	2.76	4.00	3,365	11.4	5.3	23.5
Genting	GENT MK	BUY	4.43	6.92	3,671	7.3	3.5	22.1
RGB	RGB MK	BUY	0.13	0.15	43	7.5	1.5	11.2
Gaming – NFO								
Sports Toto	SPTOTO MK	BUY	1.71	2.19	497	5.7	7.0	9.0
Magnum	MAG MK	BUY	1.41	2.00	436	12.4	4.7	17.2

Source: Bloomberg, UOB Kay Hian

OVERWEIGHT

(Maintained)

SEGMENT RECOMMENDATION

Segments	Recommendation
NFOs	OVERWEIGHT
Casino	OVERWEIGHT

Source: UOB Kay Hian

GAMING COMPANIES' RELATIVE PERFORMANCE TO FBMKLCI

Peak	Trough	Sector Average	KLCI Index	Sector vs KLCI
1-Aug-90	28-Sep-90	-28.6%	-27.2%	-1.4%
29-May-91	19-Aug-91	-2.7%	-12.1%	9.4%
25-Feb-97	1-Sep-98	-73.0%	-70.6%	-2.4%
18-Feb-00	9-Apr-01	-58.7%	-34.1%	-24.6%
11-Jan-08	29-Oct-08	-33.8%	-40.2%	6.4%
8-Jul-11	26-Sep-11	-11.2%	-12.2%	1.0%
21-Apr-15	24-Aug-15	-9.9%	-11.3%	1.4%
19-Apr-18	6-Jul-18	7.1%	-12.0%	19.1%
30-Dec-19	19-Mar-20	-26.9%	-25.0%	-1.9%
3-Mar-22	now	-3.7%	-8.9%	5.2%

Source: Bloomberg

ANALYST(S)

Vincent Khoo, CFA
+603 2147 1998
vincentkhoo@uobkayhian.com

Jack Goh
+603 2147 1983
jackgoh@uobkayhian.com

ESSENTIALS

- **Industry is unlikely to suffer from gaming duty hikes.** The government is unlikely to impose gaming duty hikes on both the casino and NFO subsectors as both subsectors have been financially wounded in the past two years due to the lockdowns. Imposing gaming duty hikes would likely also backfire on the government's need to raise revenue as duty hikes would further concede the NFO industry's market share to the illegal operators.


CASINO SEGMENT

- **GENM: Sunnier days ahead for the Malaysian operations.** We expect RWG's earnings to correlate well with rising hotel capacity (currently <80%) and operating table count as RGB expects to substantially address its foreign labour shortage by end-22.
- **Resilient US portfolio and strong contender for a New York City concession.** Following Resorts World Catskills' GGR recovering to pre-pandemic levels, associate Empire Resorts is also expected to deliver healthy EBITDA growth in 2022, and does not envision requiring any more capital injection. Meanwhile, Resorts World New York City (RWNYC), by far GENM's largest earnings contributor in the US, will fully benefit from the opening of Hyatt Regency JFK (in Aug 21) and is a strong contender for a full-fledged gaming licence in downstate New York (RFP submission expected in Oct 22). We reckon that RWNYC could eventually lift GENM's EBITDA by US\$200m-250m should it clinch a downstate casino licence, and could pave the way for a potential US listing for the Genting Group's US assets.
- **Bidding for a Macau gaming concession.** While we assign a small winning change for GENM's surprise tender for a Macau gaming concession, clinching one of the six concessions due for renewal would be uplifting to the stock's valuations.
- **GENT: GENS draws M&A interests.** Genting Group's Lim family was recently approached by MGM to discuss a takeover or investment into Genting Singapore (GENS) but the offer was rejected. We believe that MGM is trying to expand its Asian portfolio but Genting Group is not keen to part with GENS. With the world eventually fully unwinding COVID-19 curbs, we expect Genting Singapore's EBITDA to claw back to pre-pandemic level of S\$1.2b in FY23 as the worst is likely over. GENS is expected to be a lot more aggressive on the capital management trail. Meanwhile, TauRx is hosting a briefing to share its top-line data (12-month time point) from their Phase 3 trial of its Alzheimer's drug.

NFO SUBSECTOR


- **NFO subsector: Sub-optimal recovery.** We reckon that the NFOs' sales would recover to around 90% of the pre-pandemic level in 2023 (currently 80-85%), in view of the various challenges (the illegal operators' stronger network/product offerings and punters being more accustomed to rely on these operators since the pandemic).
- **Facing challenges from illegal operators.** The illegal operators have gained market share and leveraged on the COVID-19 pandemic's various restrictions. To note, the illegal operators are said to be at least 1.5-2.0x larger than the legal operators and are also offering online betting based on 4D games drawn in other countries such as Singapore and Cambodia. We think that this structural headwind will continue to persist for the NFOs until the government allows the legal NFOs to enable online operations.
- **Rooting for moderate recovery in share prices, pricing in the defensive business nature.** With the NFO subsector's revenue plateauing at 80-85% of pre-MCO levels, investors would be increasingly attracted to the subsector's earnings resilience and high dividend yield (rising to about 7% in 2023).
- **Dividends' restoration to jump-start the pandemic-low valuations.** The NFO subsector still surprisingly trades close to the lows seen during the pandemic despite fundamentally being an ideal shelter amid a risk-off market mode, given the low beta, steady cashflow streams and lush dividend yields. However, Magnum's pullback also reflects the company lowering down its dividend payout to about 80% from the pre-pandemic's >95%, to pare down debt.

MGS AND UST YIELDS



Source: Bloomberg, UOB Kay Hian

NFO SEGMENT'S YIELD



Source: Magnum, Sports Toto, UOB Kay Hian

GGR, MIX AND GROWTH OUTLOOK

Countries	2022F	2023F
Malaysia		
GGR(USD)	1.1b	1.4b
GGR Growth Forecast (%)	100-110	30-40
VIP: Mass Revenue Mix (%)	35:65	45:55

Source: UOB Kay Hian

2019 DEPENDENCY ON CHINA VIP GAMERS

Countries	GGR Dependency (%)
Malaysia	5-10

Source: UOB Kay Hian

GENT'S SOTP VALUATION

Asset	Stake	Basis	(RMm)
Genting Singapore	52.8%	TP	20,909
Genting Malaysia	49.3%	TP	11,714
Genting Plantations	50.7%	TP	2,863
Management fees		DCF	5,969
Power		EV/MW	4,245
O&G		PE	927
RWLV		DCF	9,300
Other investments and net cash			(11,252)
RNAV			44,676
Holding co discount (%)			40%
Discounted RNAV			26,806
Fully-diluted shares (m)			3,876
Target price (RM)			6.92

Source: UOB Kay Hian

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2022, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W